FDA — authorised 25 February 2015
- Application: NDA022341
- Marketing authorisation holder: NOVO NORDISK INC
- Indication: Labeling
- Status: approved
🇺🇸 Victoza in United States
FDA authorised Victoza on 25 February 2015
Marketing authorisations
FDA — authorised 2 April 2025
- Application: ANDA218115
- Marketing authorisation holder: NANJING KING FRIEND
- Status: approved
FDA — authorised 27 August 2025
- Application: ANDA214568
- Marketing authorisation holder: TEVA PHARMS
- Status: approved
FDA — authorised 14 January 2026
- Application: ANDA217590
- Marketing authorisation holder: ORBICULAR
- Status: approved
FDA — authorised 24 February 2026
- Application: ANDA217234
- Marketing authorisation holder: ORBICULAR
- Status: approved
Victoza in other countries
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Other Metabolic approved in United States
Frequently asked questions
Is Victoza approved in United States?
Yes. FDA authorised it on 25 February 2015; FDA authorised it on 2 April 2025; FDA authorised it on 27 August 2025.
Who is the marketing authorisation holder for Victoza in United States?
NOVO NORDISK INC holds the US marketing authorisation.